APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Measles Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Live Attenuated Measles Vaccine Industry Research Report 2026

Report ID 174008370529 December 2025132 pages

Choose your research edition.

Industry ResearchLive Attenuated Measles Vaccine Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Measles Vaccine Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Live Attenuated Measles Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Measles Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Measles Vaccine Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Live Attenuated Measles Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Live Attenuated Measles Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Live Attenuated Measles Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Live Attenuated Measles Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Live Attenuated Measles Vaccine include GSK, Bavarian Nordic, CSL Limited, Emergent Biosolutions, Medimmune, Sanofi-Pasteur, Serum Institute of India, Beijing Institute of Biological Products Co., Ltd and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Live Attenuated Measles Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Live Attenuated Measles Vaccine Market by Company

GSK

Bavarian Nordic

CSL Limited

Emergent Biosolutions

Medimmune

Sanofi-Pasteur

Serum Institute of India

Beijing Institute of Biological Products Co., Ltd

Pfizer

Lanzhou Institute of Biological Products Co., Ltd

Merck

Novartis

Johnson & Johnson

Shanghai Institute of Biological Products Co., Ltd

Wuhan Institute of Biological Products Co., Ltd

Changchun Qijian Biological Products Co., Ltd

Live Attenuated Measles Vaccine Segment by Type

Liquid

Powder

Live Attenuated Measles Vaccine Segment by Application

Hospital

Clinic

Live Attenuated Measles Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Measles Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Measles Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Measles Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Live Attenuated Measles Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Live Attenuated Measles Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Live Attenuated Measles Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Live Attenuated Measles Vaccine Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Live Attenuated Measles Vaccine Revenue of Manufacturers (2021-2026) Table 9. Global Live Attenuated Measles Vaccine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Live Attenuated Measles Vaccine Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Live Attenuated Measles Vaccine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Live Attenuated Measles Vaccine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Live Attenuated Measles Vaccine, Product Type & Application Table 14. Global Live Attenuated Measles Vaccine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Live Attenuated Measles Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. GSK Company Information Table 19. GSK Business Overview Table 20. GSK Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. GSK Live Attenuated Measles Vaccine Product Portfolio Table 22. GSK Recent Developments Table 23. Bavarian Nordic Company Information Table 24. Bavarian Nordic Business Overview Table 25. Bavarian Nordic Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio Table 27. Bavarian Nordic Recent Developments Table 28. CSL Limited Company Information Table 29. CSL Limited Business Overview Table 30. CSL Limited Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. CSL Limited Live Attenuated Measles Vaccine Product Portfolio Table 32. CSL Limited Recent Developments Table 33. Emergent Biosolutions Company Information Table 34. Emergent Biosolutions Business Overview Table 35. Emergent Biosolutions Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio Table 37. Emergent Biosolutions Recent Developments Table 38. Medimmune Company Information Table 39. Medimmune Business Overview Table 40. Medimmune Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Medimmune Live Attenuated Measles Vaccine Product Portfolio Table 42. Medimmune Recent Developments Table 43. Sanofi-Pasteur Company Information Table 44. Sanofi-Pasteur Business Overview Table 45. Sanofi-Pasteur Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio Table 47. Sanofi-Pasteur Recent Developments Table 48. Serum Institute of India Company Information Table 49. Serum Institute of India Business Overview Table 50. Serum Institute of India Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio Table 52. Serum Institute of India Recent Developments Table 53. Beijing Institute of Biological Products Co., Ltd Company Information Table 54. Beijing Institute of Biological Products Co., Ltd Business Overview Table 55. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 57. Beijing Institute of Biological Products Co., Ltd Recent Developments Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Pfizer Live Attenuated Measles Vaccine Product Portfolio Table 62. Pfizer Recent Developments Table 63. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 64. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 65. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 67. Lanzhou Institute of Biological Products Co., Ltd Recent Developments Table 68. Merck Company Information Table 69. Merck Business Overview Table 70. Merck Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Merck Live Attenuated Measles Vaccine Product Portfolio Table 72. Merck Recent Developments Table 73. Novartis Company Information Table 74. Novartis Business Overview Table 75. Novartis Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Novartis Live Attenuated Measles Vaccine Product Portfolio Table 77. Novartis Recent Developments Table 78. Johnson & Johnson Company Information Table 79. Johnson & Johnson Business Overview Table 80. Johnson & Johnson Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio Table 82. Johnson & Johnson Recent Developments Table 83. Shanghai Institute of Biological Products Co., Ltd Company Information Table 84. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 85. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 87. Shanghai Institute of Biological Products Co., Ltd Recent Developments Table 88. Wuhan Institute of Biological Products Co., Ltd Company Information Table 89. Wuhan Institute of Biological Products Co., Ltd Business Overview Table 90. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 92. Wuhan Institute of Biological Products Co., Ltd Recent Developments Table 93. Changchun Qijian Biological Products Co., Ltd Company Information Table 94. Changchun Qijian Biological Products Co., Ltd Business Overview Table 95. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 97. Changchun Qijian Biological Products Co., Ltd Recent Developments Table 98. Global Live Attenuated Measles Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global Live Attenuated Measles Vaccine Sales by Region (2021-2026) & (K Units) Table 100. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2021-2026) Table 101. Global Live Attenuated Measles Vaccine Sales by Region (2027-2032) & (K Units) Table 102. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2027-2032) Table 103. Global Live Attenuated Measles Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 104. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2021-2026) Table 105. Global Live Attenuated Measles Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 106. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2027-2032) Table 107. North America Live Attenuated Measles Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 109. North America Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 110. North America Live Attenuated Measles Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Live Attenuated Measles Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe Live Attenuated Measles Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 114. Europe Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 115. Europe Live Attenuated Measles Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Live Attenuated Measles Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific Live Attenuated Measles Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 119. Asia Pacific Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 120. Asia Pacific Live Attenuated Measles Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific Live Attenuated Measles Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 122. South America Live Attenuated Measles Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 124. South America Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 125. South America Live Attenuated Measles Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 126. South America Live Attenuated Measles Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 129. Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 130. Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 132. Global Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 133. Global Live Attenuated Measles Vaccine Sales by Type (2027-2032) & (K Units) Table 134. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2021-2026) Table 135. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2027-2032) Table 136. Global Live Attenuated Measles Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 137. Global Live Attenuated Measles Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 138. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2021-2026) Table 139. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2027-2032) Table 140. Global Live Attenuated Measles Vaccine Price by Type (2021-2026) & (US$/Unit) Table 141. Global Live Attenuated Measles Vaccine Price by Type (2027-2032) & (US$/Unit) Table 142. Global Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 143. Global Live Attenuated Measles Vaccine Sales by Application (2027-2032) & (K Units) Table 144. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2021-2026) Table 145. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2027-2032) Table 146. Global Live Attenuated Measles Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 147. Global Live Attenuated Measles Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 148. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2021-2026) Table 149. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2027-2032) Table 150. Global Live Attenuated Measles Vaccine Price by Application (2021-2026) & (US$/Unit) Table 151. Global Live Attenuated Measles Vaccine Price by Application (2027-2032) & (US$/Unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Live Attenuated Measles Vaccine Distributors List Table 155. Live Attenuated Measles Vaccine Customers List Table 156. Live Attenuated Measles Vaccine Industry Trends Table 157. Live Attenuated Measles Vaccine Industry Drivers Table 158. Live Attenuated Measles Vaccine Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Live Attenuated Measles Vaccine Product Image Figure 5. Global Live Attenuated Measles Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Live Attenuated Measles Vaccine Market Size (2021-2032) & (US$ Million) Figure 7. Global Live Attenuated Measles Vaccine Sales (2021-2032) & (K Units) Figure 8. Global Live Attenuated Measles Vaccine Average Price (US$/Unit) & (2021-2032) Figure 9. Liquid Product Image Figure 10. Powder Product Image Figure 11. Hospital Product Image Figure 12. Clinic Product Image Figure 13. Global Live Attenuated Measles Vaccine Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of Live Attenuated Measles Vaccine, Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 Live Attenuated Measles Vaccine Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Live Attenuated Measles Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global Live Attenuated Measles Vaccine Sales by Region in 2025 Figure 19. Global Live Attenuated Measles Vaccine Revenue by Region in 2025 Figure 20. North America Live Attenuated Measles Vaccine Market Size by Country in 2025 Figure 21. North America Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2032) Figure 22. North America Live Attenuated Measles Vaccine Revenue Market Share by Country (2021-2032) Figure 23. United States Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Europe Live Attenuated Measles Vaccine Market Size by Country in 2025 Figure 26. Europe Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2032) Figure 27. Europe Live Attenuated Measles Vaccine Revenue Market Share by Country (2021-2032) Figure 28. Germany Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. France Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. U.K. Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Italy Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Netherlands Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Asia Pacific Live Attenuated Measles Vaccine Market Size by Country in 2025 Figure 34. Asia Pacific Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2032) Figure 35. Asia Pacific Live Attenuated Measles Vaccine Revenue Market Share by Country (2021-2032) Figure 36. China Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Japan Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. South Korea Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. India Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Australia Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. China Taiwan Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Southeast Asia Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Southeast Asia Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South America Live Attenuated Measles Vaccine Market Size by Country in 2025 Figure 45. South America Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2032) Figure 46. South America Live Attenuated Measles Vaccine Revenue Market Share by Country (2021-2032) Figure 47. Mexico Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Brazil Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Argentina Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Middle East and Africa Live Attenuated Measles Vaccine Market Size by Country in 2025 Figure 51. Middle East and Africa Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2032) Figure 52. Middle East and Africa Live Attenuated Measles Vaccine Revenue Market Share by Country (2021-2032) Figure 53. Turkey Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Saudi Arabia Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. UAE Live Attenuated Measles Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2021-2032) Figure 57. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2021-2032) Figure 58. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Type (2021-2032) Figure 59. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2021-2032) Figure 60. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2021-2032) Figure 61. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Application (2021-2032) Figure 62. Live Attenuated Measles Vaccine Value Chain Figure 63. Live Attenuated Measles Vaccine Production Mode & Process Figure 64. Direct Comparison with Distribution Share Figure 65. Distributors Profiles Figure 66. Live Attenuated Measles Vaccine Industry Opportunities and Challenges

Scope & coverage.

Types
  • Liquid
  • Powder
Applications
  • Hospital
  • Clinic
Companies covered
  • GSK
  • Bavarian Nordic
  • CSL Limited
  • Emergent Biosolutions
  • Medimmune
  • Sanofi-Pasteur
  • Serum Institute of India
  • Beijing Institute of Biological Products Co., Ltd
  • Pfizer
  • Lanzhou Institute of Biological Products Co., Ltd
  • Merck
  • Novartis
  • Johnson & Johnson
  • Shanghai Institute of Biological Products Co., Ltd
  • Wuhan Institute of Biological Products Co., Ltd
  • Changchun Qijian Biological Products Co., Ltd

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Live Attenuated Measles Vaccine Market Size (2021-2032)
  4. 2.2.2 Global Live Attenuated Measles Vaccine Sales (2021-2032)
  5. 2.2.3 Global Live Attenuated Measles Vaccine Market Average Price (2021-2032)
  6. 2.3 Live Attenuated Measles Vaccine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Liquid
  9. 2.3.3 Powder
  10. 2.4 Live Attenuated Measles Vaccine by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Live Attenuated Measles Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Live Attenuated Measles Vaccine Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Live Attenuated Measles Vaccine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Live Attenuated Measles Vaccine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Live Attenuated Measles Vaccine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Live Attenuated Measles Vaccine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Live Attenuated Measles Vaccine, Product Type & Application
  8. 3.8 Global Manufacturers of Live Attenuated Measles Vaccine, Established Date
  9. 3.9 Global Live Attenuated Measles Vaccine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 GSK
  2. 4.1.1 GSK Company Information
  3. 4.1.2 GSK Business Overview
  4. 4.1.3 GSK Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 GSK Live Attenuated Measles Vaccine Product Portfolio
  6. 4.1.5 GSK Recent Developments
  7. 4.2 Bavarian Nordic
  8. 4.2.1 Bavarian Nordic Company Information
  9. 4.2.2 Bavarian Nordic Business Overview
  10. 4.2.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio
  12. 4.2.5 Bavarian Nordic Recent Developments
  13. 4.3 CSL Limited
  14. 4.3.1 CSL Limited Company Information
  15. 4.3.2 CSL Limited Business Overview
  16. 4.3.3 CSL Limited Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 CSL Limited Live Attenuated Measles Vaccine Product Portfolio
  18. 4.3.5 CSL Limited Recent Developments
  19. 4.4 Emergent Biosolutions
  20. 4.4.1 Emergent Biosolutions Company Information
  21. 4.4.2 Emergent Biosolutions Business Overview
  22. 4.4.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio
  24. 4.4.5 Emergent Biosolutions Recent Developments
  25. 4.5 Medimmune
  26. 4.5.1 Medimmune Company Information
  27. 4.5.2 Medimmune Business Overview
  28. 4.5.3 Medimmune Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Medimmune Live Attenuated Measles Vaccine Product Portfolio
  30. 4.5.5 Medimmune Recent Developments
  31. 4.6 Sanofi-Pasteur
  32. 4.6.1 Sanofi-Pasteur Company Information
  33. 4.6.2 Sanofi-Pasteur Business Overview
  34. 4.6.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio
  36. 4.6.5 Sanofi-Pasteur Recent Developments
  37. 4.7 Serum Institute of India
  38. 4.7.1 Serum Institute of India Company Information
  39. 4.7.2 Serum Institute of India Business Overview
  40. 4.7.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio
  42. 4.7.5 Serum Institute of India Recent Developments
  43. 4.8 Beijing Institute of Biological Products Co., Ltd
  44. 4.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
  45. 4.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
  46. 4.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  48. 4.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
  49. 4.9 Pfizer
  50. 4.9.1 Pfizer Company Information
  51. 4.9.2 Pfizer Business Overview
  52. 4.9.3 Pfizer Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Pfizer Live Attenuated Measles Vaccine Product Portfolio
  54. 4.9.5 Pfizer Recent Developments
  55. 4.10 Lanzhou Institute of Biological Products Co., Ltd
  56. 4.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  57. 4.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  58. 4.10.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  60. 4.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  61. 4.11 Merck
  62. 4.11.1 Merck Company Information
  63. 4.11.2 Merck Business Overview
  64. 4.11.3 Merck Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Merck Live Attenuated Measles Vaccine Product Portfolio
  66. 4.11.5 Merck Recent Developments
  67. 4.12 Novartis
  68. 4.12.1 Novartis Company Information
  69. 4.12.2 Novartis Business Overview
  70. 4.12.3 Novartis Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Novartis Live Attenuated Measles Vaccine Product Portfolio
  72. 4.12.5 Novartis Recent Developments
  73. 4.13 Johnson & Johnson
  74. 4.13.1 Johnson & Johnson Company Information
  75. 4.13.2 Johnson & Johnson Business Overview
  76. 4.13.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio
  78. 4.13.5 Johnson & Johnson Recent Developments
  79. 4.14 Shanghai Institute of Biological Products Co., Ltd
  80. 4.14.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  81. 4.14.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  82. 4.14.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  84. 4.14.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  85. 4.15 Wuhan Institute of Biological Products Co., Ltd
  86. 4.15.1 Wuhan Institute of Biological Products Co., Ltd Company Information
  87. 4.15.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
  88. 4.15.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  90. 4.15.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
  91. 4.16 Changchun Qijian Biological Products Co., Ltd
  92. 4.16.1 Changchun Qijian Biological Products Co., Ltd Company Information
  93. 4.16.2 Changchun Qijian Biological Products Co., Ltd Business Overview
  94. 4.16.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  96. 4.16.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
5 Global Live Attenuated Measles Vaccine Market Scenario by Region
  1. 5.1 Global Live Attenuated Measles Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Live Attenuated Measles Vaccine Sales by Region: 2021-2032
  3. 5.2.1 Global Live Attenuated Measles Vaccine Sales by Region: 2021-2026
  4. 5.2.2 Global Live Attenuated Measles Vaccine Sales by Region: 2027-2032
  5. 5.3 Global Live Attenuated Measles Vaccine Revenue by Region: 2021-2032
  6. 5.3.1 Global Live Attenuated Measles Vaccine Revenue by Region: 2021-2026
  7. 5.3.2 Global Live Attenuated Measles Vaccine Revenue by Region: 2027-2032
  8. 5.4 North America Live Attenuated Measles Vaccine Market Facts & Figures by Country
  9. 5.4.1 North America Live Attenuated Measles Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Live Attenuated Measles Vaccine Sales by Country (2021-2032)
  11. 5.4.3 North America Live Attenuated Measles Vaccine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Live Attenuated Measles Vaccine Market Facts & Figures by Country
  15. 5.5.1 Europe Live Attenuated Measles Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Live Attenuated Measles Vaccine Sales by Country (2021-2032)
  17. 5.5.3 Europe Live Attenuated Measles Vaccine Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Live Attenuated Measles Vaccine Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Live Attenuated Measles Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Live Attenuated Measles Vaccine Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Live Attenuated Measles Vaccine Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Live Attenuated Measles Vaccine Market Facts & Figures by Country
  35. 5.7.1 South America Live Attenuated Measles Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Live Attenuated Measles Vaccine Sales by Country (2021-2032)
  37. 5.7.3 South America Live Attenuated Measles Vaccine Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Live Attenuated Measles Vaccine Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Live Attenuated Measles Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Live Attenuated Measles Vaccine Sales by Type (2021-2032)
  2. 6.1.1 Global Live Attenuated Measles Vaccine Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Live Attenuated Measles Vaccine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Live Attenuated Measles Vaccine Revenue by Type (2021-2032)
  5. 6.2.1 Global Live Attenuated Measles Vaccine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Live Attenuated Measles Vaccine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Live Attenuated Measles Vaccine Sales by Application (2021-2032)
  2. 7.1.1 Global Live Attenuated Measles Vaccine Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Live Attenuated Measles Vaccine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Live Attenuated Measles Vaccine Revenue by Application (2021-2032)
  5. 7.2.1 Global Live Attenuated Measles Vaccine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Live Attenuated Measles Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Live Attenuated Measles Vaccine Value Chain Analysis
  2. 8.1.1 Live Attenuated Measles Vaccine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Live Attenuated Measles Vaccine Production Mode & Process
  5. 8.2 Live Attenuated Measles Vaccine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Live Attenuated Measles Vaccine Distributors
  8. 8.2.3 Live Attenuated Measles Vaccine Customers
9 Global Live Attenuated Measles Vaccine Analyzing Market Dynamics
  1. 9.1 Live Attenuated Measles Vaccine Industry Trends
  2. 9.2 Live Attenuated Measles Vaccine Industry Drivers
  3. 9.3 Live Attenuated Measles Vaccine Industry Opportunities and Challenges
  4. 9.4 Live Attenuated Measles Vaccine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst